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O-GlcNAcylation is an O-linked β-N -acetylglucosamine (O-GlcNAc) moiety linked to the
serine or threonine residues in proteins. O-GlcNAcylation is a dynamic post-translational
modification involved in a wide range of biological processes and diseases such as cancer.
This modification can increase and decrease the activity of enzymes as well as interfere
with protein stability and interaction. The modulatory capacity of O-GlcNAcylation, as well
as protein phosphorylation, is of paramount importance in the regulation of metabolism and
intracellular signaling of tumor cells.Thus, understanding the regulation of O-GlcNAcylation
in tumor cells and their difference compared to non-tumor cells may elucidate new mech-
anisms related to tumor generation and development, could provide a new marker to
diagnosis and prognosis in patients with cancer and indicate a new target to cancer
chemotherapy.
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INTRODUCTION
O-linked β-N -acetylglucosamine (O-GlcNAc) was discovered
30 years ago (1). Unlike “traditional glycosylation,” O-GlcNAc is
not elongated into more complex structures and is localized mainly
in nucleocytoplasmic compartments. The addition of O-GlcNAc
to proteins is catalyzed by O-GlcNAc transferase (OGT), and the
O-GlcNAcase (OGA) catalyzes its removal (2). Deletion of OGT
is lethal in mice at the embryonic level and at the single-cell level,
highlighting the importance of O-GlcNAcylation in regulating
basic cellular events (3). Similar to phosphorylation, O-GlcNAc
is an abundant, dynamic, and inducible post-translational modi-
fication (PTM) occurring on serine and threonine residues. The
relationship between phosphorylation and O-GlcNAcylation is
more complex than initially thought not only in terms of site
occupancy, where both PTMs occur on Ser/Thr and can modulate
each other (2) but also O-GlcNAc can regulate Tyr phosphoryla-
tion, indicating that interplay between these PTMs at the substrate
level is not limited to Ser and Thr residues (4). Therefore, growing
evidences suggest that O-GlcNAcylation regulate kinases and/or
phosphatases (5–7), making the relationship between these two
PTMs even more complex. Approximately 1000 proteins have been
described to be O-GlcNAcylated to date (8). Like phosphorylation,
O-GlcNAcylation can modulate protein function, including enzy-
matic activity, protein turnover, protein interactions, subcellular
localization, DNA affinity, and transcription activity (2).
The hexosamine biosynthetic pathway (HBP) is a branch of
the glucose metabolic pathway, consuming approximately 2–5%
of the total glucose (9). The first and limiting step of the HBP
is catalyzed by glutamine: fructose-6-phosphate amidotransferase
(GFAT) that converts fructose-6-phosphate to glucosamine-6-
phosphate with the concomitant conversion of glutamine to
glutamate. Glucosamine-6-phosphate is further metabolized to
UDP-GlcNAc, which serves as the monosaccharide donor for O-
GlcNAcylation. UDP-GlcNAc is considered an ideal sensor for the
metabolic status of the cell, as it requires glucose, glutamine, acetyl-
Coenzyme-A, and nucleotide uridine-5′-triphosphate (UTP).
Nutrient-sensitive changes the flux through the HBP either
increasing or decreasing UDP-GlcNAc levels, affecting the O-
GlcNAcylation of many proteins, since OGT is highly sensitive
to UDP-GlcNAc levels across a very broad range of concentrations
(10). Several O-GlcNAcylated proteins are involved in the devel-
opment and pathology of major diseases such as cancer, diabetes
and Alzheimer’s disease (11, 12).
Cancer is a multifactorial disease characterized by the uncon-
trolled proliferation of cells. Tumor cells have altered glucose
metabolism, producing ATP primarily through glycolysis, even
under normoxic conditions. This metabolic shift was termed the
“Warburg effect”and involves up-regulation of glucose uptake and
is critical for supporting a malignant phenotype (13). The high
rate of glycolytic flux is a central metabolic hallmark of tumors.
An increase of about 10-fold more glucose incorporation has been
demonstrated in several types of human cancers than in adjacent
normal tissue. Increased expression of GLUT1 has been shown
in various types of cancer (14). This phenomenon of elevated
glucose uptake has been clinically exploited to detect tumor cells
by positron emission tomography (PET) scans (15). Glutamine
is a key nutrient for tumors cells, being a major source of nitro-
gen and energy in rapidly dividing cells. Recently, Itkonen and
colleagues showed that several HBP genes were overexpressed in
human prostate cancers (16). This phenomenon has been spec-
ulated for several years due to the suggestive increased uptake of
glucose and glutamine in tumor cells. The link between altered
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metabolism and glycosylation through HBP provides a mecha-
nism for the cancer cells to sense and respond to a variety of
environmental conditions. It is already known that HBP flux can
alters cell surface O-Glycans (17) and N -Glycans (18), but our
focus here will be O-GlcNAc. Several studies have related para-
meters of tumor development with O-GlcNAc (Figure 1). Many
signaling pathways become deregulated during the transformation
due to a gain of function of oncogenes and a loss of function of
tumor suppressors. O-GlcNAcylation modulates several tumor-
associated proteins including p53, c-Myc, beta-catenin, Ras, and
NF-κB, among others. About 60 papers have been published in
the last 3 years relating O-GlcNAc and cancer. A substantial num-
ber of them have related the increase of O-GlcNAc and OGT
in several types of tumors [for review see Ref. (19, 20)]. Many
authors have reported that the levels of O-GlcNAc and the pro-
tein expression of OGT and OGA are aberrant in different models,
including cell lines, murine models, and human tumor samples.
Recently, some authors have associated O-GlcNAcylation with
prognosis and tumor grade. Below, we summarize the changes
of O-GlcNAc levels and the cycling enzymes in different tumor
types (Figure 2).
O-GlcNAc DYNAMICS IN DIFFERENT TUMOR TYPES
BREAST CANCER
Alterations in O-GlcNAcylated protein levels as well as OGT
and OGA levels are well established for breast cancer. Studies
show that both cell lines and patient samples contain elevated
O-GlcNAcylation and increased OGT levels (21–23). Gu and col-
leagues (21) showed by immunochemistry that O-GlcNAc modi-
fication is elevated in human breast tumor tissue when compared
with adjacent normal tissue. In the same direction, Krzeslak et al.
(24) demonstrated that patient samples have more OGT mRNA
and less OGA mRNA than normal samples. In addition, Champat-
tanachai and colleagues (23) confirmed by immunoblotting that
patient samples have elevated levels of OGT and O-GlcNAc when
compared with normal patient samples. When analyzing breast
tumor cell lines, Caldwell et al. (22) showed the same correla-
tion between normal and tumor cells, where the tumor cell lines
appeared to contain more O-GlcNAc modification and elevated
levels of OGT when compared to normal cell lines. There was also
an association between O-GlcNAc, OGT, and OGA levels with
breast tumor malignancy. Tumor progressions were accompanied
by increased levels of OGT mRNA and decreasing OGA mRNA
(24). Champattanachai et al. (23) showed an increase of OGT pro-
tein and O-GlcNAc levels related to the histological grade of breast
tumors. In oppose direction, Slawson and colleagues (25) showed,
in a reduced sample size, an increase in OGA activity with breast
cancer tumor grade.
PROSTATE CANCER
Lynch and colleagues (26) showed that O-GlcNAc and OGT levels
are higher and OGA/OGT ratios are lower in tumor cells than in
normal cells lines. This diminished ratio may lead to the higher
O-GlcNAcylation. In addition, they examined OGT expression
using the Oncomine™ Database and found elevated OGT mRNA
expression patterns in human prostate carcinoma compared with
normal adjacent tissue in more than 200 patient samples. With
respect to tumor progression, the authors searched the National
Center for Biotechnology Information (NCBI) database and found
a positive correlation between high OGT expression and metasta-
tic progression in normal, primary tumor, and metastatic prostate
tumor tissues. The OGT levels were also analyzed as prognostic
factors and it was observed that disease-free survival 5 years post-
treatment for prostate cancer was higher in patients with a low
OGT expression profile compared with patients with increased
OGT expression (26). In this direction, Kamigaito and colleagues
(27) also proposed that the increase of O-GlcNAc levels as a
prognostic factor, because they observed a significant association
between this PTM and a poor patient prognosis in a 5-year overall
survival analysis in 56 patients.
FIGURE 1 |Variation of the parameters involved in tumorigenesis by modulating the levels of O-GlcNAcylation.
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FIGURE 2 | Schematic representation of O-GlcNAc dynamics in different types of tumor.
COLON CANCER
Studies showed an increase of O-GlcNAc and OGT levels in patient
samples by immunochemistry and immunoblotting, but OGA lev-
els were not modified when compared with normal colon tissue
(28, 29). Using primary and metastatic colon cancer cell lines
derived from the same patient, Yehezkel and colleagues showed
that metastatic cells have increased levels of O-GlcNAcylated pro-
teins and reduced OGA, indicating a relationship with malignity
(30). However, no significant difference between the cell lines was
found for OGT. They also showed that both OGT and OGA are
more readily detected in the cytoplasm than in the nucleus of colon
tumor cells (30).
BLADDER CANCER
Studies involving O-GlcNAc and bladder cancer are directed
toward diagnosis and prognosis. Investigation of the presence of
the mRNA of O-GlcNAc cycling enzymes was performed by real-
time PCR assay using the urine of 176 patients and 143 health
persons. OGT mRNA was present in more than half of the urine
samples from bladder cancer patients, but was not found in the
urine of healthy patients. Therefore, the analysis of urinary con-
tent of OGA and OGT mRNA may be useful for bladder cancer
diagnostics. Moreover, OGT expression was significantly higher in
grade II and III in comparison to grade I bladder cancer indicating
a potential in prognosis (31).
LEUKEMIA
The O-GlcNAc dynamics in a leukemia model is poorly known,
but chronic lymphocytic leukemia (CLL) patients present with
increased O-GlcNAc levels in lymphocytes when compared with
those from normal blood samples. OGT and OGA levels were not
investigated. However, unlike the results observed in other tumor
types, low O-GlcNAc levels were associated with more aggressive
CLL (32).
ENDOMETRIAL CANCER
Krzeslak and colleagues (33) determined the O-GlcNAc cycling
enzymes mRNA levels for endometrial cancer using real-time
RT-PCR analysis of 76 patient samples. Both OGT and OGA
mRNA expression was significantly higher in high grade tumors
than in low grade ones. They also showed an association
between OGT and OGA expression and myometrial invasion
(33), indicating that O-GlcNAcylation can be related to aggres-
siveness.
LIVER CANCER
Liver transplantation represents the treatment of choice for
patients with early stage of hepatocellular carcinoma (HCC).
However, frequent tumor recurrence following transplant remains
the major obstacle for long-term survival. Zhu et al. (34) demon-
strated that patients who had suffered from tumor recurrence
after liver transplantation during the follow-up period had an
enhanced O-GlcNAcylation level compared to those who had been
recurrence free. Patients with low OGA expression in tumors
had an increasing risk of tumor recurrence after liver trans-
plantation, indicating that OGA expression may have prognostic
value for HCC. OGT expression was not correlated with HCC
prognosis (34).
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PANCREATIC CANCER
Following the patterns seen for other tumors, analysis of O-
GlcNAc levels in pancreatic tumors and normal patient tissues
by immunochemistry showed that tumor samples have increased
levels of O-GlcNAc. Measuring normal pancreas and tumor cell
lines showed that OGT protein levels in tumors were higher than
in normal cell lines and that OGA levels were decreased (35).
LUNG CANCER
Immunochemistry analysis of patient samples showed that O-
GlcNAc and OGT has the same alterations found in other tissues,
with increased protein levels in tumor tissues when compared
with adjacent healthy tissue, and that OGA levels appear to be
unaltered (28).
THYROID CANCER
In oppose direction, Krzeslak et al. (36) showed that O-
GlcNAcylated protein levels are decreased in thyroid tumors and
accompanied by an increase of OGA activity. They also observed
that most of the O-GlcNAcylated proteins were found in the
nucleus.
These studies demonstrate that O-GlcNAcylation is indeed
altered in tumors in general when compared to normal tissues.
However, there is no general rule about the variation in the levels
of this modification or its relationship with prognosis, since dif-
ferent tumor tissues may have different levels of O-GlcNAc and
influence on prognosis.
O-GlcNAc IN METABOLIC REPROGRAMING
The main carbon source of cancer cells is glucose, and besides
increased glucose uptake, cancer cells display increased glycol-
ysis and lactate production, even in the presence of oxygen;
this is known as the Warburg effect. This phenotype is impor-
tant as it provide intermediates for other anabolic pathways.
Metabolic reprograming is an essential characteristic achieved
by cancer cells to support proliferation (37). Tumor cells are
often exposed to a heterogeneous microenvironment with dif-
ferent nutrient and oxygen availabilities (38). O-GlcNAcylation
is a nutrient-sensitive PTM that responds to changes of the sugar
donor UDP-GlcNAc. Growing evidence indicates that O-GlcNAc
is a crucial mechanism linking cancer metabolism and cellular
signaling (Figure 3) (16, 19, 20).
GLYCOLYSIS
As a point of convergence of metabolic pathways, it is expected
that O-GlcNAcylation can exert a strong influence on cellular
metabolism and the enzymes that perform catalysis. Not sur-
prisingly, several glycolytic enzymes can be O-GlcNAcylated (23,
39). Yi et al. (40) demonstrated that both OGA inhibition and
OGT overexpression decreased PFK1 activity, as well as glycolytic
rate and lactate production. They demonstrated that PFK1 O-
GlcNAcylation at serine 529 was essential to decrease the PFK1
activity, diverting glucose-6-phosphate to the pentose phosphate
pathway (PPP), and conferring a growth advantage to cancer cells
FIGURE 3 | Metabolism regulation by O-GlcNAcylation in tumor cells.
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by producing more NAPDH, which is an important component
of the antioxidant system. In the same report, they examined
the impact of OGT overexpression on hexokinase (HK), phos-
phoglycerate kinase (PGK), and pyruvate kinase (PK) activities.
Although they have not evaluated their direct O-GlcNAcylation
status, they showed that HK activity was increased while PGK and
PK activities were decreased under those conditions. Champat-
tanachai et al. (23) employed a proteomic strategy to compare the
profile of O-GlcNAcylated proteins between benign and grade III
breast tumors. They identified several proteins that were hyper-O-
GlcNAcylated in cancer tissues; among them, four were glycolytic
enzymes: enolase 2, triosephosphate isomerase, PK, and glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH). They confirmed
GAPDH and PKM2 O-GlcNAcylation by immunoprecipitation
assays. Interestingly, GAPDH and PKM2 are also known for their
non-glycolytic roles in cancer, which may also be regulated by
O-GlcNAc.
GLUTAMINE
As well as glucose,glutamine (Gln) is an essential nutrient for many
cancer cells. After entering the cell through specific transporters
like SLC1A5, Gln can be consumed in the HBP pathway, but most
of it is converted into glutamate (Glu) by glutaminases (Gls). Glu
can then have three fates: it can be converted into α-ketoglutarate
by glutamate dehydrogenase to produce Krebs cycle intermediates;
it can be used to produce glutathione (GSH), together with glycine
and cysteine; or can be converted to non-essential aminoacids by
transaminases. Gls 1 and 2 expression is regulated by c-Myc and
p53, respectively. c-Myc-overexpressing cells become Gln addicted
since they have increased levels of GLS1 (41). PDAC cells utilize a
different Gln pathway and have been shown to be extremely depen-
dent on glucose and glutamine, but curiously not dependent on
NADPH produced by the PPP. However, to deal with the damaging
reactive oxygen species, they use a pathway depending on aspar-
tate aminotransferase (Got) to convert aspartate into oxaloacetate,
which is then converted into malate and finally into pyruvate by
malic enzyme producing NADPH (42). Some cancer cells, how-
ever, are not dependent on the supply of Gln because they are
able to synthesize their own from glucose. Glutamine synthetase
(Glul) catalyzes the conversion of glutamate into glutamine and
the dependence on this pathway seems to rely on the oncogene
activated and the tissue of origin (41, 43). Glutamate dehydroge-
nase, both Got isoforms and Glul can be O-GlcNAcylated (39).
These modifications may be exploited by cancer cells in favor of
growth and metastasis.
KREBS CYCLE AND MITOCHONDRIA
The connection between glycolysis and the Krebs cycle is per-
formed by pyruvate dehydrogenase (PDH), which transforms
pyruvate into acetyl CoA. PDH can be phosphorylated and inhib-
ited by pyruvate dehydrogenase kinase (PDK), which is often
up-regulated in cancer. Inhibition of PDH decreases mitochon-
drial function, contributing to the Warburg effect that is typical
of cancer cells; PDK has been proposed as a therapeutic target in
many cancers (44). O-GlcNAcylation of the alpha and beta sub-
units of PDH have also been demonstrated by Clark et al. (39)
and as an important point of regulation, it would be interesting
to understand its function. In 2003, Love et al. demonstrated
that a smaller isoform of OGT was enriched in mitochondrial
extracts. Further characterization showed a mitochondrial target-
ing sequence and a membrane domain in the N-terminus (45).
However, mOGT overexpression induced apoptosis by an unclear
mechanism and it was dependent on its catalytic activity (46).
Clark et al. (39) demonstrated by 2D electrophoresis and mass
spectrometry that many mitochondrial proteins in the rat fore-
brain could be O-GlcNAcylated. They identified the protein sub-
units alpha and beta of ATP synthase and two proteins from com-
plex I: Ndufs 1 and Ndufs 2. In addition, the exposure of cardiac
myocytes to high glucose medium increased O-GlcNAcylation of
mitochondrial proteins, impaired mitochondrial function and led
to decreased ATP pools. O-GlcNAcylation of the mitochondrial
proteins COXI and NDUFA9 were identified by immunoprecipi-
tation and both were more O-GlcNAcylated after exposure to high
glucose (47). Tan et al. (48) also demonstrated that overexpression
of OGT and OGA affected mitochondria morphology and mito-
chondrial localization of Krebs cycle and respiratory chain proteins
leading to decreased respiration and glycolysis.
Importantly, mitochondria are dynamic organelles that can be
remodeled by fusion or fission. These processes are controlled
by mitofusin 1/2 (MFN1/2) and dynamin-related protein (Drp1),
respectively. The role of these processes in cancer is not completely
clear, but increased Drp1 expression has already been demon-
strated in many tumors and may confer selective advantage to
cancer cells (49–51). Drp1 can be O-GlcNAcylated in cardiac
myocytes at threonine 585 and 586 after treatment with OGA
inhibitors. These modifications decrease the phosphorylation of
serine 637 and increases Drp1 translocation to the mitochondria
and its activity. Increased Drp1 activity leads to mitochondria frag-
mentation and reduces membrane potential (52). Thus, increased
mitochondria fragmentation and protein O-GlcNAcylation could
be related in cancer.
O-GlcNAcylation REGULATION OF TUMOR FORMATION,
MAINTENANCE, AND DISSEMINATION
O-GlcNAc IN PROLIFERATION AND SURVIVAL OF TUMOR CELLS
Tumor cell maintenance is essential for tumor development and
O-GlcNAc has a substantial function in the proliferation and sur-
vival of tumor cells. Two different groups have demonstrated
that O-GlcNAcylation could modulate the growth of prostate
tumor cells. In the LNCaP cell line, siRNA-mediated OGT knock-
down resulted in decreased proliferation compared with control-
transfected cells (27). In the same direction, Lynch and colleagues
showed, using a PC3-ML cell line, an 80% reduction in the
anchorage-independent growth of OGT shRNA-expressing cells
compared with control cells. The ability of OGT knockdown cells
to grow in a three-dimensional culture was significantly impaired
by 65% compared with control cells. However, non-transformed
OGT knockdown cells RWPE-1 did not demonstrate significant
changes of growth in a three-dimensional culture (26). An increase
of O-GlcNAc by PUGNAc or siRNA against OGA in the thyroid
tumor 8305C cell line also increased cell viability and proliferation
(36). In addition, Ma and colleagues showed that pancreatic tumor
cell line PDAC, silenced for OGT display, reduced cell prolifera-
tion and anchorage-independent growth. However, knockdown of
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OGT in non-transformed HPDE prostate cells did not affect their
proliferation (35). These results indicate that O-GlcNAcylation is
important for tumor cell growth and cancer cells appear to be
specifically susceptible to loss of OGT, suggesting that this enzyme
may be a potential future therapeutic target in chemotherapy.
Caldwell and co-workers demonstrated that mice injected with
OGT knockdown breast tumor cells showed a fourfold reduction
in tumor volume and mass when compared with injected con-
trol cells. At necropsy, 84% of mice injected with cells expressing
scrambled shRNA developed visible tumors, against 40% of mice
injected with cells containing OGT shRNAs. The authors pointed
out that tumors that eventually grew from OGT knockdown cells
restored OGT expression, suggesting a selective pressure against
tumor cells that are deficient in OGT (22). Another study showed
that pancreatic tumor cells with OGT knockdown injected into
mice also resulted in greatly reduced tumor growth or even no
tumor formation (35). These data indicate the importance of OGT
in tumor cell growth in vivo.
In a model of 3D cell culture, Onodera et al. (53) demonstrated
a direct relationship between glucose uptake and cell transforma-
tion. Knockdown of the glucose transporter Glut3 or lowering
the levels of glucose concentration in the media led to decreased
EGFR and MEK phosphorylation and β1 integrin expression as
well as increased organization of the cells in acini. Using glycol-
ysis inhibitor and PKM2 knockdown, they demonstrated PKM2
could interact with soluble adenylyl cyclase leading to activation
of the EPAC/RAP1 pathway, responsible for regulating β1 inte-
grin expression and cell polarization. However, this pathway did
not interfere dramatically into EGFR and MEK activation. Fur-
ther analysis showed increased glucose uptake led to the activation
of these pathways through HBP pathway and that the phenotype
could be reversed by addition of GFTP and OGT inhibitors.
Besides the link between O-GlcNAcylation and cell prolifera-
tion/growth, the relationship between O-GlcNAc and tumor cell
survival were observed. The reduction of O-GlcNAcylation in
prostate tumor cells lines decreased the expression of the anti-
apoptotic protein Bcl-xL and induced the pro-apoptotic cleavage
of caspases-9, and -3, suggesting that reducing O-GlcNAc lev-
els leads to activation of the intrinsic apoptotic pathway (35).
Thus, O-GlcNAc may have a role in protecting tumor cells from
apoptosis. Interestingly, this protection appears to be specific to
tumor cells, because reducing O-GlcNAcylation by OGT knock-
down of non-transformed HPDE cells did not trigger apoptosis
(35). In addition, Kanwal and colleagues observed the same pro-
tective role of O-GlcNAc modification in breast tumor cells. They
demonstrated that increased O-GlcNAcylation in MCF-7 cells
had inhibitory effects on Tamoxifen-induced cell death, while
O-GlcNAcylation reduction sensitized tumor cells to Tamoxifen
treatment (54).
Taken together, O-GlcNAc is involved in tumor formation,
growth, and survival in vivo. Furthermore, high levels of O-
GlcNAcylated proteins seem to promote tumor cell proliferation
and, may contribute to the specific resistance of tumor cells to
spontaneous apoptosis induced by chemotherapies. The acqui-
sition of multidrug resistance (MDR) phenotype by tumors is a
major cause of cancer treatment failure (55),and according to Kan-
wal’s work, O-GlcNAc levels correlate with the acquisition of this
phenotype in breast tumor cells, but more studies using different
cell types and tumors are needed to establish this relationship.
O-GlcNAc IN METASTASIS
A crucial event for tumor development and dissemination is
the acquisition of invasiveness. Cells with this ability can invade
and migrate, generating metastasis. A significant decrease of cell
migration and invasion in three different breast cell lines with
OGT knockdown was observed when compared with the nega-
tive control. Importantly, OGA inhibition markedly increased cell
migration and invasion of breasts cell lines (21, 56), pointing to an
important role for O-GlcNAc in migration. The treatment with
OGT inhibitors of MCF-10A-ErbB2 and MDA-MB-231 breast
tumor cells decreased the cell migration using Transwell assays
(22). OGT knockdown in the PC3-ML prostate tumor cell line
also reduced their ability to migrate when compared with control
cells (26). Another study using prostate tumor cells LNCaP siRNA-
mediated OGT knockdown also decreased tumor cell invasion
when compared with control siRNA-transfected cells (27).
Gu et al. (21) showed that in 4T1 cells OGT knockdown do not
display significant differences in primary tumor weights. However,
a dramatic reduction of visible metastatic nodules on the lung
surface was observed. Moreover, Lynch and co-workers injected
into mice highly bone metastatic prostate tumor cells (PC3-ML),
silenced or not for OGT; after 5 weeks, animals injected with OGT
knockdown cells had fourfold less bone metastases to mandibles
and hind limbs. Surprisingly, the histological analysis showed that
the PC3-ML cells forming the metastatic focus display normal
OGT levels (26). These results support the functional role for OGT
in breast and prostate metastasis.
Proteins of the matrix metalloproteinase (MMP) family are
involved in extracellular matrix degradation in physiological
processes such as metastasis. However, the mechanism involving
O-GlcNAc and the invasion of tumor cells is still poorly under-
stood. Alterations in MMP proteins levels can be modulated by
O-GlcNAc. Knockdown of OGT led to a significant decrease in the
expression of MMP-2 at both the mRNA and protein level com-
pared with controls in breast, liver, and prostate tumor cells (22,
26, 34) and OGA silencing resulted in the up-regulation of MMP-2
(34). The OGT knockdown of prostate tumor cells showed marked
reductions of FoxM1 protein levels (26). It should be noted that
FoxM1 is a transcription factor that regulates MMP-2 expression,
suggesting that OGT regulates cancer cell invasion by modulating
MMP-2 expression. In addition, MMP-9 also showed a 50% reduc-
tion in its expression in OGT knockdown cells (26), and MMP-1
and MMP-3 were increased when the O-GlcNAcylation level was
enhanced and decreased when O-GlcNAcylation was reduced (34).
A recent work demonstrated the O-GlcNAcylation at serine
108 in cofilin, a major regulator of actin dynamics that drives
cell motility. Breast tumor cell lines overexpressing OGT con-
siderably increased cell mobility. When the OGT-overexpressing
cells were silenced for cofilin, the OGT-enhanced cell mobility
was almost entirely reversed. In addition, mutant cells expressing
S108A cofilin, showed an apparent defect in invasion compared
with the wild-type cells (56). These data suggest that cofilin mod-
ification by O-GlcNAc is involved in tumor cell mobility and
invasion.
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ONCOGENES, TUMOR SUPPRESSORS, AND PROTEINS
INVOLVED IN TUMOR BIOLOGY THAT ARE REGULATED BY
O-GlcNAc
c-Myc
c-Myc is a proto-oncogene that acts as transcription factor regu-
lating cell cycle and replication. The c-Myc protein is expressed in
normal cells at low levels, but overexpressed in transformed and
proliferative cells (57). Deregulation of c-Myc gene expression is
one of the most frequently encountered events in human cancer,
and is implicated in over half of all malignancies (58). c-Myc is gly-
cosylated at Thr58 (59), a known phosphorylation site that leads
to c-Myc degradation (60). Proximal to this site, the phosphoryla-
tion of Ser62 stimulates its activity, promoting cell transformation
(60). Although the exact influence of O-GlcNAc modification on
c-Myc is not known, O-GlcNAcylation of Thr58 would reduce the
phosphorylation of this site, stabilizing c-Myc. Recently, Itkonen
and colleagues showed that OGT levels are correlated with c-Myc
protein levels but not with c-Myc mRNA levels, indicating that
the effect of OGT on c-Myc levels is in the stability of the pro-
tein (16). Thus, the effect of O-GlcNAcylation of c-Myc would
improve its transformation capacity, favoring tumor growth, but
studies are needed to observe the cell phenotype produced by
c-Myc O-GlcNAcylation.
p53
p53 is a tumor suppressor that is involved in DNA damage repair
and the induction of apoptosis. The p53 mutation prevents the
DNA repair and induction of apoptosis favoring tumor cell sur-
vival. The p53 gene is one of the most prevalent genes mutated in
tumor cells, being mutated in more than 50% of human cancers.
p53 is O-GlcNAcylated on Ser149 and this modification stabi-
lizes p53 and decreases p53-MDM2 interactions, by decreasing the
phosphorylation on Thr 155, which is a known site that induces
ubiquitination and degradation (61). In addition, overexpression
of OGA increases MDM2 phosphorylation at Ser 166 (62), which
stimulates MDM2-p300 interactions and results in p53 degrada-
tion. Higher levels and stabilization of p53 by elevated O-GlcNAc
would lead to a higher tumor suppression activity, disfavoring
tumor progression; however, p53 in tumors is usually mutated
and less functional, so stabilization of mutated p53 by glycosyla-
tion should not lead to a significant tumor suppression in most
tumors. Indeed, some cancers can present p53 mutants that con-
tain Pro or Phe instead of Ser at the position 149 (63, 64), disabling
the presence of O-GlcNAc. So far, the impact of this change in p53
transcriptional activity is not known.
RAS
Ras is a family of transmembrane GTPases involved in signal
transduction that leads to cell proliferation. Mutations in RAS
genes occur in 30% of all tumors (65) and lead to a constitutively
activated Ras conformation. This oncogene is highly activated in
human cancers appearing in 90% of pancreatic tumors (66) and
50% of colon tumors (67). K-Ras has a role in HBP as it con-
trols GFAT levels; K-Ras depletion results in the inhibition of HBP
and decreased protein O-GlcNAcylation (68). K-Ras appears to
be an important regulator of glucose metabolism in tumor cells
and has an involvement in O-GlcNAcylation cell status (69). Ying
and colleagues (68) demonstrated a complete regression of fully
established tumors 1 week after K-Ras extinction, underscoring
the role of the HBP and hyper-O-GlcNAcylation in controlling
tumor maintenance.
AMPK
AMPK is an important energy sensor enzyme responsible for reg-
ulating cellular metabolism in response to substrate availability. It
is activated by AMP and ADP, while it is inhibited by ATP. Its acti-
vation enhances catabolic pathways and decreases many anabolic
pathways important for cancer cell growth, making of it an excel-
lent therapeutic target. It is a heterotrimeric enzyme composed of
a catalytic subunit α and regulatory subunits β and γ. There are
several isoforms for each subunit, which can interact to form 12
different complexes (70). Since O-GlcNAc signaling can also act
as an energy sensing pathway, a significant crosstalk between them
is expected although it has not been deeply exploited yet.
Neuronal glucose deprivation leads to up-regulation of OGT
expression and increased O-GlcNAcylation of proteins in a AMPK
pathway dependent manner (71). In myotubes, Bullen et al. (72)
demonstrated AMPK phosphorylates T444 of OGT in vitro, which
correlates with OGT nuclear accumulation. In addition, OGT can
also O-GlcNAcylate AMPK subunits α and γ and inhibition of
O-GlcNAc cycling by TMG treatment mitigate AMPK activation.
Finally, they have also demonstrated, in proliferating cells, that
AMPK activation affects OGT substrate selectivity (72).
NF-κB
NF-κB is a transcription factor involved in cell proliferation, sur-
vival, and inflammation. This pathway can be activated in normal
cells in certain occasions, but abnormal constitutive NF-κB activa-
tion has been linked to oncogenic growth/survival of many cancer
types (73). Five NF-κB family members have been identified in
humans but the most prevalent and best studied is a dimer com-
posed of p65 (RelA) and p50 subunits. In unstimulated cells, this
dimer is localized in the cytoplasm where it binds its inhibitor
(IκB). Treatment with TNFα or other activating agents stimu-
lates IκB kinase (IKK), which phosphorylates IκB inducing its
degradation via an ubiquitin-dependent proteolysis. Free NF-κB
translocates to the nucleus and activates the expression of target
genes (74).
It is well established that NF-κB is modulated by the PTMs
by phosphorylation, ubiquitination, and acetylation. However,
growing evidences demonstrates that O-GlcNAcylation of NF-
κB is also related to its activation. NF-κB subunit p65 (RelA) is
O-GlcNAcylated on the Thr322 and Thr352 residues (35, 75),
but only modification on Thr352 is important for NF-κB tran-
scriptional activity (75). Further, site-directed mutagenesis of the
threonines 322 and 352 of p65 led to decreased colony formation
(35). Another study shows the presence of O-GlcNAc on Thr305
of NF-κB. The p65 (T305A) mutant is not acetylated by p300, link-
ing the O-GlcNAc and acetylation events. Reconstitution of RelA
null cells with the RelA (T305A) mutant are deficient for NF-κB
transcription, and are more sensitive to TNF-induced apoptosis,
indicating the importance of this residue for NF-κB-dependent
gene expression and cell survival (76). In addition, the increase in
glucose uptake by tumor cells results in O-GlcNAcylation of the
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IKKβ subunit at Ser733 causing IkB degradation, and maintaining
NF-κB in the constitutively activated form in tumor cells (77).
Hyper-O-GlcNAcylation, through the pharmacological inhibition
of OGA, increases IKKα O-GlcNAcylation, accompanied by the
activation of NF-κB signaling (35). These data propose a new reg-
ulation in tumor cells that promotes tumor growth and survival
by the maintenance of the over activated NF-κB pathway in these
cells.
CONCLUSION AND FUTURE DIRECTIONS
Taken together, O-GlcNAc appears to be important in tumor biol-
ogy, and altered O-GlcNAcylation is an event found in many types
of cancer. This aberrant O-GlcNAcylation correlates with aug-
mented tumor cell proliferation and survival, increased tumor
formation, invasion, metastasis, and resistance to therapy. These
events point to several interesting conclusions: (1) the use of O-
GlcNAcylation as diagnosis factor : once transformed cells exhibit
higher or lower levels of this PTM, the accurate determination of
this level change may be a biomarker of cellular malignancy in
some tumor types. However, further studies should be conducted
to validate it. Importantly, the levels of protein glycosylation are
not determinant to characterize a transformed cell, but its varia-
tion compared to normal tissue. Remembering that the amount
of O-GlcNAc levels in tumor cells varies from tissue to tissue,
establishing specific parameters would therefore be important for
each tumor type. (2) The use of O-GlcNAcylation as prognostic fac-
tor : the literature already describes that O-GlcNAcylation could
be used as a prognostic factor for some types of tumor as for,
e.g., prostate and leukemia. Once parameters for each tissue are
established it will be possible to speculate about the tumor grade,
tumor proliferation, survival and response to treatment of these
patients. In addition, the search for aberrant O-GlcNAcylation of
specific key proteins may help the discovery of new cancer markers
or prognostic factors. (3) O-GlcNAcylation as therapeutic target in
cancer : many metabolic pathways intersect on UDP-GlcNAc syn-
thesis pathway, HBP, making it an important metabolic sensor.
Considering metabolic reprograming as a hallmark of cancer and
the evidence showing that normal cells are less influenced by inter-
ventions in the levels of O-GlcNAcylation, is possible to suggest
that therapies targeting the O-GlcNAc enzymes, OGT and OGA,
or the O-GlcNAcylated form of specific proteins may have ther-
apeutic potential. Importantly, the lower sensitivity to O-GlcNAc
manipulation in normal cells may lead to fewer side effects than
many chemotherapy drugs used in the clinic today, improving the
quality of life of patients. For the development of in vivo studies, it
is important to remember that OGT and OGA knockouts are not
viable. One possible solution for this impasse would be the devel-
opment of more efficient and specific inhibitors of OGT and OGA.
The choice of an appropriate concentration could decrease or
impair cancer cell proliferation minimizing adverse effects to nor-
mal cells. In addition, studies aimed at obtaining specific inhibitors
of OGT that act on key target proteins are important for further
progress in this area.
However, for the application of any of the alternatives men-
tioned, larger studies are needed to define the profile of O-GlcNAc
modifications for each type of tissue and its relationship to diag-
nosis and prognosis, in addition to studies seeking novel proteins
important in tumor signaling that are modified by O-GlcNAc. It
is not known whether increased O-GlcNAcylation is the cause or
consequence of cancer, and it is still too early to indicate the exact
role of O-GlcNAcylation in the pathology of different cancer types.
However, collectively, these studies indicate that O-GlcNAc has
potential in diagnosis, prognosis evaluation and as a therapeutic
target in cancer.
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